Total de visites
| Visites | |
|---|---|
| Intracranial ... | 63 |
Total de visites per mes
| d’octubre 2023 | de novembre 2023 | de desembre 2023 | de gener 2024 | de febrer 2024 | de març 2024 | d’abril 2024 | |
|---|---|---|---|---|---|---|---|
| Intracranial ... | 0 | 0 | 0 | 1 | 1 | 3 | 1 |
Total de descàrregues del fitxer
| Visites | |
|---|---|
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021.pdf | 24 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula5.pdf | 14 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula2.pdf | 13 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula3.pdf | 13 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula1.pdf | 12 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_figura1.pdf | 11 |
| intracranial_and_extracranial_efficacy_lorlatinib_patients_alk_positive_non_small_cell_lung_cancer_previously_treated_second_generation_alk_tkis_2021_taula4.pdf | 9 |
Visites per país
| Visites | |
|---|---|
| Estats Units | 39 |
| Espanya | 10 |
| Canadà | 6 |
| Alemanya | 2 |
| Regne Unit | 2 |
| Bèlgica | 1 |
| Xipre | 1 |
| Finlàndia | 1 |
| França | 1 |
Visites per ciutat
| Visites | |
|---|---|
| Chandler | 11 |
| Barcelona | 7 |
| Ashburn | 5 |
| Chicago | 5 |
| Québec | 3 |
| Beauharnois | 2 |
| London | 2 |
| Boardman | 1 |
| Brussels | 1 |
| Des Moines | 1 |